CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Biopharma
LifeMine Therapeutics Announces $50 Million Series B Financing
Proceeds will enable advancement and acceleration of the Company’s transformative drug discovery programs derived from digital search of the fungal biosphere to discover and develop highly impactful precision medicines...